The short answer
Extra sedation from passionflower with ropinirole has not been demonstrated. Because some passionflower preparations carry a driving caution and ropinirole can cause sudden sleep episodes, review a sleep product with your pharmacist before adding it.
What this answer covers
Passiflora incarnata herb preparations, not fruit, another species or an assumed equivalent mixed product.
- Supplement or preparation
- Passiflora incarnata
- Medication ingredient
- ropinirole
Why passionflower raises a question
The European monograph recognizes traditional use of specified passionflower herb preparations as a sleep aid and warns that they may impair driving. Ropinirole independently has a warning about sleepiness and sudden sleep episodes.
The small trials did not show extra sedation
Two short studies around surgery did not find greater sedation with the tested passionflower products than with placebo. They did not test ropinirole or ongoing sleep-product use.
Check which preparation you have
The monograph lists no reported interactions, which does not prove this combination safe. Bring the plant part, extract and full ingredient list to your pharmacist. The evidence does not establish a spacing interval that prevents impairment.
When daytime sleepiness needs attention
Contact your prescriber promptly for new marked daytime sleepiness or falling asleep during ordinary activities. Do not drive or use machinery if this occurs. Ropinirole can cause sleep episodes even without a warning feeling of drowsiness; the treating team should decide how to change treatment.
Evidence and practical considerations
Side effects & toxicity
Traditional-use guidance supports a cautious alertness review, while short trials did not show greater sedation.
- Exact scope
- Passiflora incarnata herb preparations, not fruit, another species or an assumed equivalent mixed product. with Oral immediate-release ropinirole, with hydrochloride salt expressed as equivalent free base in label section 11.
- Medication form and route
- oral
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- No ropinirole co-use trial; short perioperative results cannot define chronic combined exposure.
Factors that may matter: baseline alertness; exact preparation; other medicines; treatment indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
No direct study of these six supplement combinations. Immediate-release tablet context does not establish release-form or dose interchangeability.
Source 2: official guidance
ema.europa.eu · Source check Sep 10, 2026
Population: People considering the specified supplement.
Traditional sleep-aid use; may impair driving. Section 4.5 lists no reported interactions.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Traditional-use monograph, not a ropinirole trial. No reported interaction is not proof of safety.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults undergoing ambulatory surgery.
Anxiety decreased, but sedation and psychomotor recovery were similar between groups.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Short perioperative exposure to one product, no ropinirole; does not establish chronic combination safety.
Source 4: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults aged 25-55 undergoing spinal anesthesia.
No significant group differences in sedation, psychomotor function, hemodynamics or side effects.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Selected perioperative population, no ropinirole; not proof that all preparations lack impairment.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Targeted sources inspected and all current available claims adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: a65bc099d34150f2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.